Auxotrophic recombinant BCG strain pasteur and usethereof in the control of human infections caused by parasites

The present invention relates to a vaccinal strain of recombinant BCG Mycobacterium bovis expressing the Schistossoma mansoni Sm14 protein (BCG Pasteur ”leuD/p”K410-hsp60*-Sm14). The vaccinal strain of the present invention is employed in the control of infections caused by parasites, specially the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	VILAR MONICA MAGNO, TENDLER MIRIAM, MCINTOSH DOUGLAS
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a vaccinal strain of recombinant BCG Mycobacterium bovis expressing the Schistossoma mansoni Sm14 protein (BCG Pasteur ”leuD/p”K410-hsp60-Sm14). The vaccinal strain of the present invention is employed in the control of infections caused by parasites, specially the Schistossoma mansoni. The vaccinal strain is a an auxotrophic strain to leucine amino acid derived from the BCG Pasteur sub-strain complemented to leucine after genetic transformation with the construct p”K410-hsp60-Sm14. The efficacy of the BCG Pasteur ”leuD/p”K410-hsp60*-Sm14 strain in the control of the Schistossoma mansoni infection based on the recombinant Sm14 antigen in vivo is showed in the present invention.